Tumor regression after neoadjuvant chemotherapy in locally advanced colon cancer

Tumor regression after neoadjuvant chemotherapy in locally advanced colon cancer

Background. Our aim was to investigate efficacy of neoadjuvant chemotherapy in colon cancer based on tumor regression.Materials and methods. This retrospective study included colon cancer patients, who underwent treatment at the department of oncoproctology of Russian N. N. Blokhin Cancer Research C...

Full description

Bibliographic Details
Main Authors:	A. O. Rasulov, V. M. Kulushev, V. S. Ananiev, M. Yu. Fedyanin, N. A. Kozlov
Format:	Article
Language:	Russian
Published:	“ABV-press” Publishing house”, LLC 2015-10-01
Series:	Тазовая хирургия и онкология
Subjects:	neoadjuvant chemotherapy adjuvant chemotherapy large bowel cancer colon cancer locally advanced cancer therapeutic pathomorphism of tumor xelox regimen folfox regimen distant metastases
Online Access:	https://ok.abvpress.ru/jour/article/view/141

Similar Items

Metronomic chemotherapy regimens in oncology
by: M. Yu. Fedyanin, et al.
Published: (2016-04-01)

Feasibility and Safety of Perioperative Chemotherapy With Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel for Locally Advanced Gastric Cancer Patients in China
by: Birendra Kumar Sah, et al.
Published: (2021-01-01)

A retrospective study of pembrolizumab combined with XELOX regimen in the treatment of advanced gastric cancer
by: FENG Huizhi, LIU Jingmei, BU Xiaoqian
Published: (2024-11-01)

Neoadjuvant chemotherapy for colon cancer
by: M. Yu. Fedyanin, et al.
Published: (2022-06-01)

The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial
by: Qun Zhao, et al.
Published: (2020-08-01)

A Retrospective Study of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
by: Wang Y, et al.
Published: (2020-09-01)

Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience
by: Jianhong Peng, et al.
Published: (2019-10-01)

Neoadjuvant chemotherapy for patients with locally advanced penile cancer: an updated evidence
by: Xian-Yan-Ling Yi, et al.
Published: (2022-01-01)

Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer
by: Shirin Kianersi, et al.
Published: (2023-01-01)

Feasibility Study of a Modified XELOX Adjuvant Chemotherapy for High-Recurrence Risk Patients With Operated Stage III Colon Cancer
by: Jianhong Peng, et al.
Published: (2020-09-01)

Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer
by: Ren Hui, et al.
Published: (2011-09-01)

Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?
by: Nabil Ismaili, et al.
Published: (2011-09-01)

KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer
by: Yanhong Deng, et al.
Published: (2015-08-01)

Early Start of Chemotherapy after Resection of Primary Colon Cancer with Synchronous Multiple Liver Metastases:A Case Report
by: Yoichiro Yoshida, et al.
Published: (2011-05-01)

Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study
by: Tsunekazu Mizushima, et al.
Published: (2019-09-01)

Iron Deficiency Anemia as The Only Manifestation of Colon Cancer in Male Patient: A Case Report
by: Wulyo Rajabto, et al.
Published: (2020-12-01)

Clinical Significance of has_circ_0055625 in Colon Cancer Patients Undergoing FOLFOX Chemotherapy Treatment
by: Liu X, et al.
Published: (2021-01-01)

Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer
by: Jin Ye Fu, et al.
Published: (2023-02-01)

Application of Nab-paclitaxel combined with gemcitabine in neoadjuvant chemotherapy laparoscopic followed by pancreatoduodenectomy to a patient with pancreas head cancer invading to protal vein
by: Chunyan Li, et al.
Published: (2022-11-01)

Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients
by: Yu S, et al.
Published: (2020-10-01)

Feasibility study of adjuvant chemotherapy with S-1 after curative esophagectomy following neoadjuvant chemotherapy for esophageal cancer
by: Noriyuki Hirahara, et al.
Published: (2022-06-01)

Quality of life changes during adjuvant chemotherapy in patients with colon cancer
by: Seo Hee Lee, et al.
Published: (2016-06-01)

Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)
by: Keisuke Miwa, et al.
Published: (2021-01-01)

Clinical Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy on Muscle-invasive Bladder Cancer
by: DENG Kangli, et al.
Published: (2019-04-01)

XELOX doublet regimen versus EOX triplet regimen as first‐line treatment for advanced gastric cancer: An open‐labeled, multicenter, randomized, prospective phase III trial (EXELOX)
by: Xiao‐Dong Zhu, et al.
Published: (2022-04-01)

Adverse Effects of Chemotherapy Regimens Used in Colorectal Cancer Patients in a Referral Cancer Center in North of Iran, 2008-2014
by: Ebrahim Salehifar, et al.
Published: (2017-09-01)

Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer
by: Serhat Sekmek, et al.
Published: (2023-11-01)

A randomized phase 3 trial of total neoadjuvant therapy (induction chemotherapy, neoadjuvant chemoradiation, neoadjuvant chemotherapy, and surgery) vs. standard long-term chemoradiation therapy (neoadjuvant chemoradiation, surgery, and adjuvant chemotherapy) in locally advanced rectal cancer
by: Freshte Foroughi, et al.
Published: (2024-12-01)

Neoadjuvant Doxorubicin-Paclitaxel Combined Chemotherapy in Patients with Inoperable Stage III Breast Cancer: A Retrospective Cohort Study with 10 Years of Follow-Up in Vietnam
by: Duc Thanh Le, et al.
Published: (2023-06-01)

Effectiveness of neoadjuvant chemotherapy with a docetaxel, cisplatin, and S-1 (DCS) regimen for T4b gastric cancer
by: Vo Duy Long, et al.
Published: (2024-12-01)

Short-term outcomes of neoadjuvant chemotherapy in colorectal cancer patients with isolated liver metastasis
by: A. Yu. Dobrodeev, et al.
Published: (2023-01-01)

Early Start of Chemotherapy after Resection of Brain Metastasis from Colon Cancer with Synchronous Multiple Liver Metastases
by: Yoichiro Yoshida, et al.
Published: (2012-06-01)

5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
by: Takuo Yamai, et al.
Published: (2022-04-01)

Clinically applicable 53-Gene prognostic assay predicts chemotherapy benefit in gastric cancer: A multicenter study
by: Linghua Zhu, et al.
Published: (2020-11-01)

Long-term effects of neoadjuvant chemotherapy in variant histology locally advanced colon cancer: a propensity score-matched analysis
by: Qiancheng Wang, et al.
Published: (2025-12-01)

Patients achieved pCR during neoadjuvant chemotherapy had better outcome than adjuvant chemotherapy setting in breast cancer: A comparative study
by: Jida Chen, et al.
Published: (2023-01-01)

Propensity Score Matched Study of Tri-Weekly vs. Weekly Platinum-Based Chemotherapy Concurrent with Radiotherapy in the Treatment of Locally Advanced Cervical Cancer
by: Kullathorn Thephamongkhol, et al.
Published: (2022-04-01)

Prognostic factors in patients with locally advanced breast cancer treated with neoadjuvant taxane-anthracycline combination chemotherapy
by: Chang-Eun Jang, et al.
Published: (2015-12-01)

High-risk bladder cancer: improving outcomes with perioperative chemotherapy
by: Daniel Y.C. Heng, et al.
Published: (2011-12-01)

High-risk bladder cancer: improving outcomes with perioperative chemotherapy
by: Daniel Y.C. Heng, et al.
Published: (2011-12-01)